trial

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

NCTId NCT02477020
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 164 (actual)
Sponsored by Takeda
Primary completion 2016-07-13
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
164 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-07-01
Primary completion
2016-07-13
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
TAK-063 20 mg

Sponsors

TakedaLead Sponsor

Sites

0 total

Linked catalysts

1
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exa — primary completion2016-07-13

Facts & assertions

4 sourced
Enrollment
164
Phase
PHASE2
Primary Completion Date
2016-07-13
Status
COMPLETED
relationships
The graph out of here
drug
TAK-063 20 mg
drug
lead_sponsor
Takeda
company
indication
Schizophrenia
indication
Schizophrenia
indication